Top

Branko Cuglievan, MD

Department of Pediatrics, Division of Pediatrics

About Dr. Branko Cuglievan

Dr. Cuglievan completed his Pediatric training in Miami Children's Hospital, and he subsequently completed both Pediatric Hematology and Oncology training at MD Anderson, during which he was selected the Chief Fellow. He obtained board certification in Pediatrics and Pediatric Hematology and Oncology and stayed on faculty as Assistant Professor in the Department of Pediatrics.

Dr. Cuglievan focuses on Pediatric Leukemia and Lymphoma and collaborates extensively with the prestigious adult divisions of Leukemia and Lymphoma and is either the principal investigator or the pediatric collaborator for several pivotal trials that cover the Adolescents and Young Adult (AYA) population. Additionally, he leads the Pediatric Leukemia and Lymphoma service at Memorial Hermann Children's Hospital.

His translational research work is done in collaboration with the Massachusetts Institute of Technology and Harvard University and has been focused on the implementation of biomedical engineering devices to accelerate drug discovery for pediatric cancer. He has received several awards, including the Young Investigator Hyundai Hope on wheels, Tridelta Foundation award, and the Men of Distinction Foundation award. Dr. Cuglievan has authored/co-authored several publications and book chapters and serves as MD Anderson's Faculty Ambassador for MLS' Houston Dynamo.

Primary Appointment

Associate Professor (Joint Appointment), Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas

Associate Professor, Department of Pediatrics - Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas

Section Chief, Leukemia/Lymphoma, Department of Pediatrics Patient Care, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor, Department of Pediatrics - Patient Care, The University of Texas at MD Anderson Cancer Center, Houston, Texas

Research Interests

Biomedical Engineering to accelerate drug discovery in Childhood Cancer

Education & Training

Degree-Granting Education

2010	Universidad de San Martin de Porres, Facultad de Medicina Humana, Lima, PE, MD
2009	Harvard Medical School, Boston Children's Hospital, Boston, Maine, US, Pediatrics in Pediatrics
2001	Markham College, Lima, PE, Bilingual Diploma in International Baccalaureate

Postgraduate Training

2015-2018	Clinical Fellowship, Pediatric Hematology-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
2013-2015	Clinical Residency, Pediatrics, Miami Children's Hospital, Miami, Florida
2012-2013	Clinical Internship, Pediatrics, Miami Children's Hospital, Miami, Florida

Licenses & Certifications

2019	The American Board of Pediatric Hematology-Oncology
2018	Texas Medical Board
2015	The American Board of Pediatrics

Experience & Service

Faculty Academic Appointments

Assistant Professor, Department of Pediatrics Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2024

Administrative Appointments/Responsibilities

Co-Director for Translational Research in Pediatric Leukemia and Lymphoma, Department of Pediatrics - Patient Care, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present

Head of Data & Safety Monitoring Board (DSMB) for clinical trial PARPAML, Pediatric Oncology Experimental Therapeutics Investigators’ Consortium (POETIC) which is run out of Stanford University, 2023 - Present

Section Chief, Department of Pediatrics Patient Care, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2022 - Present

Section Chief ad interim, Leukemia/Lymphoma, Department of Pediatrics Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - 2022

On-Call Scheduler (Pedi Hema/Onc), Department of Pediatrics Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2018

Triage Scheduler (Faculty/App/Fellows), Department of Pediatrics Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2018

Morbidity & Mortality Conference Scheduler, Department of Pediatrics Patient Care, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2018

Other Professional Positions

Member, Infectious Disease Committee, Miami Children's Hospital, Miami, FL, 2015

Representative of Class 2015, Miami Children's Hospital, Miami, FL, 2012 - 2015

Physician, Clinica Anglo Americana, Lima, 2010 - 2012

Member, Academic Commission, Universidad San Martin de Porres, Lima, 2006

Member, Student Council, Universidad San Martin de Porres, Lima, 2005

Extramural Institutional Committee Activities

Chair, Data and Safety Monitoring Board, The University of Texas MD Anderson Cancer Center, 2024 - Present

Search Committee Interviewer- Dr. Sheetal Phadnis, Pediatric Neuro Onc Candidate Search Committee, The University of Texas MD Anderson Cancer Center, 2023

Search Committee Interviewer- Vijaya Ramachandran, PhD, Project Director Candidate Search Committee, The University of Texas MD Anderson Cancer Center, 2023

Search Committee Interviewer - Dr. Jeremy Connors, SCTCT Faculty Candidate Search Committee, The University of Texas MD Anderson Cancer Center, 2023

Search Committee Interviewer - Dr. Irtiza Sheikh, SCTCT Faculty Candidate Search Committee, The University of Texas MD Anderson Cancer Center, 2023

Member, Molecular Testing Executive Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present

Member, Executive Leadership Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present

Member, NCCN Pediatric Hodgkin Lymphoma Panel, The University of Texas MD Anderson Cancer Center, 2022 - Present

Member, NCCN Pediatric Mature B Cell Lymphoma Panel, The University of Texas MD Anderson Cancer Center, 2020 - 2023

Chair, Pediatric Educational Committee, The University of Texas MD Anderson Cancer Center, 2020 - 2024

Member, Scientific Research Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2021

Member, Faculty Academic Review Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2022

Chair, Pediatrics Hematology/Oncology Fellowship Program Evaluation Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present

Committee Representative for Pediatrics, Clinical Learning Environment Review (CLER), The University of Texas MD Anderson Cancer Center, 2018 - Present

Member, Pediatric Division Travel Policy Committee, The University of Texas MD Anderson Cancer Center, 2018 - Present

Member, Ewing's Sarcoma and Osteosarcoma Working Group, The University of Texas MD Anderson Cancer Center, 2017 - Present

Member, Pediatric Leukemia/Lymphoma Working Group, The University of Texas MD Anderson Cancer Center, 2017 - Present

Member, Pediatric Education Working Group, The University of Texas MD Anderson Cancer Center, 2017 - Present

Member, Pediatrics Clinical Practice Committee, The University of Texas MD Anderson Cancer Center, 2017 - Present

Honors & Awards

2021	Texas Super Doctors Rising Stars
2020	Men of Distinction, The University of Texas MD Anderson Cancer Center
2020	Excellence in Education Award, The University of Texas MD Anderson Cancer Center
2019 - 2020	TriDelta Foundation Award
2018	Chief Fellow, The University of Texas MD Anderson Cancer Center
2018	Young Investigator Award, Hyundai Hope on Wheels
2018	Elected representative for the Clinical Learning Environment Review (CLER) committee for Pediatrics, The University of Texas MD Anderson Cancer Center
2018	Nominee for the Resident/Fellow Excellence Award for Professionalism, The University of Texas MD Anderson Cancer Center
2015	"Speed Data-ing” Fellowship Award, The University of Texas MD Anderson Cancer Center
2015	The Ramon Rodriguez Award for Preventative Pediatric Medicine, Miami Children's Hospital
2015	The Augustin Castellanos Resident of the Year Award, Miami Children's Hospital
2015	1st Place Award - 7th Annual Scholarship Day, Miami Children's Hospital
2014	1st Place Award - 6th Annual Scholarship Day, Miami Children's Hospital
2014	Award for Excellence in Pediatric Hematology/Oncology, Miami Children's Hospital
2013	1st Place Award - 5th Annual Scholarship Day, Miami Children's Hospital
2012 - 2014	Resident of the Month, Miami Children's Hospital
2003	Ranked #1 Medical School Admission Exam - Int'l Baccalaureate Category, Universidad San Martin de Porres
2002	President, Markham College
2001	Perfect Leadership Award, Markham College

Professional Memberships

American Society for Clinical Oncology

2016 - Present

American Academy of Pediatrics

2016 - Present

American Society of Pediatric Hematology/Oncology

2016 - Present

Children's Oncology Group

2016 - Present

Connective Tissue Oncology Society

2016 - Present

Selected Presentations & Talks

Local Presentations

2025. Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenib in Patients With Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia. Poster. AMCP 2025. Houston, Texas, US.
2025. Childhood Leukemias: Updates, Challenges, and Collaborative Solutions to Transform Care. Invited. Texas Children’s Cancer and Hematology Center Research Seminar. Houston, Texas, US.

Regional Presentations

2024. Updates in Pediatric Leukemia 2024. Invited. Mixed Session Journal Club/Research. Houston, TX, US.
2014. The Role of NAMPT-NAD-Sirtuin Pathway in Neuroblastoma Chemoresistance (Award Ceremony) - Grand Rounds. Conference. The Role of NAMPT-NAD-Sirtuin Pathway in Neuroblastoma Chemoresistance (Award Ceremony) - Grand Rounds. Miami, FL, US.
2014. Emerging New Therapy for Neuroblastoma in Children: My Personal Experience - Grand Rounds. Conference. Emerging New Therapy for Neuroblastoma in Children: My Personal Experience - Grand Rounds. Miami, FL, US.
2014. Targeting Glioblastoma Stem Cells with Withaferin A. Cancer Research Day. Conference. Targeting Glioblastoma Stem Cells with Withaferin A. Cancer Research Day. Miami, FL, US.
2014. Withaferin A as a Novel Differentiating Agent for Treatment of Neuroblastoma. 6th Annual Residents and Fellows Scholarship Day/Research Day. Conference. Withaferin A as a Novel Differentiating Agent for Treatment of Neuroblastoma. 6th Annual Residents and Fellows Scholarship Day/Research Day. Miami, FL, US.
2013. Epstein Barr Infection Obscuring Pediatric Chronic Eosinophilic Leukemia Associated t(1;5) With Excellent Response to Targeted Therapy. Award Ceremony - Grand Rounds. Conference. Epstein Barr Infection Obscuring Pediatric Chronic Eosinophilic Leukemia Associated t(1;5) With Excellent Response to Targeted Therapy. Award Ceremony - Grand Rounds. Miami, FL, US.

National Presentations

2026. AUGMENT-101 KMT2Ar. Poster. HOPA 2026. New Orleans, Louisiana, US.
2025. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Predicting and improving outcomes in common and rare subgroups of pediatric ALL. Conference. 67th ASH Annual Meeting and Exposition. Orlando, Florida, US.
2025. Post-transplant maintenance with revumenib in children with HOX-driven AML. Conference. 67th ASH Annual Meeting and Exposition. Orlando, Florida, US.
2025. AUGMENT 101 - KMT2Ar. Conference. 67th ASH Annual Meeting and Exposition. Orlando, Florida, US.
2025. Advancing Pediatric Oncology Through Smarter Trial Design and Advocacy. Invited. LLS Dare to Dream Summit 2025. Washington, D.C, US.
2025. Transforming outcomes in Pediatric AML. Invited. High Risk Leukemia Seminar.
2025. COG APAl2020k Updates. Conference. COG Fall 2025 Group Meeting. New Orleans, Louisiana, US.
2025. COG APAl2020k Updates. Conference. COG Spring Virtual Group Meeting 2025, US.
2024. Accelerating Agents for Childhood Cancer. Invited. Syndax Commercial and Field Medical Meeting. Las Vegas, Nevada, US.
2024. COG APAl2020k Updates. Conference. COG Fall 2024 Group Meeting. New Orleans, Louisiana, US.
2024. Evolving Treatment Strategies in Pediatric Leukemia. Invited. Evolving Treatment Strategies in Pediatric Leukemia CE/CME Webinar, US.
2024. Pediatric AML. Diagnostic Methodologies. Invited. Syndax HOLI: Hematology Oncology Learning Institute: A Clinical Immersion in Acute Leukemias (AML & ALL) - DAY 2. Houston, TX, US.
2024. Treatment of Pediatric Acute Leukemia. Invited. Syndax HOLI: Hematology Oncology Learning Institute: A Clinical Immersion in Acute Leukemias (AML & ALL) - DAY 1. Houston, TX, US.
2023. Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study. Conference. 65th ASH Annual Meeting & Exposition. San Diego, Ca, US.
2023. Clinical utility of a novel non-invasive device for monitoring severe neutropenia induced by anticancer therapy (Poster). Conference. Clinical utility of a novel non-invasive device for monitoring severe neutropenia induced by anticancer therapy (Poster). Chicago, IL, US.
2023. Optical genome mapping for cytogenomic analysis of hematological neoplasms (Poster). Conference. Optical genome mapping for cytogenomic analysis of hematological neoplasms (Poster). Chicago, IL, US.
2023. Dianostic Uncertainty Due to Pre-Biopsy Steroids to Treat Malignant Superor Vena Cava Syndrome. Conference. Dianostic Uncertainty Due to Pre-Biopsy Steroids to Treat Malignant Superor Vena Cava Syndrome. Forth Worth, TX, US.
2023. Early Unfavorable Classic Hodgkin Lymphoma Treated with A+AVD in a Pediatric Patient. Conference. Early Unfavorable Classic Hodgkin Lymphoma Treated with A+AVD in a Pediatric Patient. Forth Worth, TX, US.
2023. Menin Inhibition in Pediatric KMT2Ar Leukemia: Phase 1 and Expanded Access Experience With Revumenib. Conference. Syndax. Fort Worth, TX, US.
2023. Pediatric Pure Erythroid Leukemia-An ongoing Diagnostic and Therapeutic Conundrum. Conference. Pediatric Pure Erythroid Leukemia-An ongoing Diagnostic and Therapeutic Conundrum. Forth Worth, TX, US.
2023. Successful Treatment of Malignancy-Associated Hemophagocytic Lymphohistiocytosis in a Teenager. Conference. Successful Treatment of Malignancy-Associated Hemophagocytic Lymphohistiocytosis in a Teenager. Forth Worth, TX, US.
2023. Remission with an Adult Regimen in a Teenager with Blastic Plasmacytoid Dendritic Cell Neoplasm. Conference. Remission with an Adult Regimen in a Teenager with Blastic Plasmacytoid Dendritic Cell Neoplasm. Forth Worth, TX, US.
2023. ASTEX727 + Ven. Conference. ASTEX727 + Ven, US.
2023. Treatment Advancements for Acute Lymphoblastic Leukemia (ALL) In Children and Adults. Conference. KIME Global LLC, US.
2022. APAL2020K Phase I study of KO-539 in combination with FLA in children KMT2Ar, NUP98r and NPM1c Leukemia. Conference. APAL2020K Phase I study of KO-539 in combination with FLA in children KMT2Ar, NUP98r and NPM1c Leukemia. New Orleans, LA, US.
2022. APAL2020K: A Phase I Trial of KO-539 in Combination with Fludarabine and Cytarabine (FLA) for Children with Relapsed/Refractory KMT2Ar, NUP98r, and NPM1c Leukemias, National Talk. Conference. APAL2020K: A Phase I Trial of KO-539 in Combination with Fludarabine and Cytarabine (FLA) for Children with Relapsed/Refractory KMT2Ar, NUP98r, and NPM1c Leukemias, National Talk, US.
2021. Acute Lymphoblastic Leukemia. Conference. Acute Lymphoblastic Leukemia.

International Presentations

2025. Advancements in Pediatric Leukemia. Invited. Congreso Peru.
2025. NK-cell trials for AML. Conference. The 9th New Agents in Leukemia/Lymphoma. Amsterdam, NL.
2024. APAL2020K updates. Invited. 66th Annual Meeting of the American-Society-of-Hematology (ASH). San Diego, US.
2024. APAL2020K/Kura. Invited. 66th Annual Meeting of the American-Society-of-Hematology (ASH). San Diego, US.
2024. Pediatric Leukemia: An overview. Invited. Lima, PE.
2023. New drugs new toxicities? Differentiation syndrome with Menin inhibition. Conference. The 8th Pediatric Oncology New Agents in Leukemia/Lymphoma. Amsterdam, NL.

Formal Peers

2023. PTCT Seminar: Challenges & Opportunities to incorporate targeted therapies in children & adolescents with AML. Invited, US.

Less

Grant & Contract Support

Date:	2025 - 2027
Title:	Targeted Protein Degradation of MYC in Relapsed/Refractory Pediatric AML
Funding Source:	Children’s Cancer Research Fund (CCRF)
Role:	Co-I

Date:	2024 - 2028
Title:	Co-targeting menin, RAS, and BCL-2 in KMT2A-rearranged pediatric acute leukemias
Funding Source:	V Foundation
Role:	Co-I

Date:	2024 - 2026
Title:	c-MYC Protein Degradation in Therapy-resistant Pediatric Leukemias
Funding Source:	CURE Childhood Cancer
Role:	Co-I

Date:	2024 - 2028
Title:	Studies to Characterize and overcome Menin inhibitor resistance in pediatric AML with MLL rearrangement
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI
ID:	RP240180

Date:	2024 - 2026
Title:	Studies to characterize and overcome Menin inhibitor resistance in pediatric AML with MLL rearrangement
Funding Source:	Institutional Research Grant
Role:	PI

Date:	2023 - 2024
Title:	Fibrinogen supplementation for acquired fibrinogen deficiency in acute leukemia: A single-center retrospective study
Funding Source:	Octapharma USA, Inc
Role:	PI

Date:	2022 - 2025
Title:	PedAL Sub-trial APAL2020B – IMGN632
Funding Source:	Leukemia and Lymphoma Society
Role:	PI

Date:	2022 - 2026
Title:	Epigenetic Targeting of B-cell Lymphoma
Funding Source:	B- Cell lymphoma Moonshot Program Grant
Role:	CO-I

Date:	2022 - 2026
Title:	Targeting the SMARCA4 Mutation in Pediatric Burkitt Lymphoma
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	CO-I

Date:	2021 - 2023
Title:	Non-Invasive White Blood Cells
Funding Source:	Center for Advancing Point of Care Technologies in Heart, Lung, Blood and Sleep Disorders’ (CAPCaT)
Role:	PI
ID:	R44CA228920

Date:	2021 - 2027
Title:	Predictors of Systemic Exposure to Oral 6MP During Maintenance in Adolescents and Young Adults with Acute Lymphoblastic Leukemia
Funding Source:	NIH Research Project Grant
Role:	PI
ID:	PA-19-056

Date:	2020 - Present
Title:	An in Vivo Micro-Scale Implantable Device in Pediatric Malignancies
Funding Source:	Men of Distinction
Role:	PI

Date:	2020 - Present
Title:	Pre-Clinical Drug Testing through an in Vivo Micro-Scale Implantable Device in Relapsed CAR T Cell Lymphoma PDXs
Funding Source:	Andrew Sabin Foundation Award. Research Grant
Role:	PI

Date:	2020 - Present
Title:	Mouse Models in Leukemia
Funding Source:	NIH
Role:	CO-I
ID:	CA258250

Date:	2020 - Present
Title:	CRLF2 Antibody Generation for Pediatric ALL
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	CO-I

Date:	2019 - Present
Title:	An in Vivo Micro-Scale Implantable Device in Pediatric Malignancies
Funding Source:	TriDelta
Role:	PI

Date:	2019 - Present
Title:	Ewing’s Sarcoma Single Cell Analysis
Funding Source:	Funding Agency (grant #) Alex Lemonade Stand
Role:	CO-I

Date:	2019 - Present
Title:	HL Single Cell Analysis
Funding Source:	Young Investigator Award
Role:	PI

Date:	2018 - 2021
Title:	Pre-Clinical Drug Testing through an in Vivo Micro-Scale Implantable Device in Ewing Sarcoma PDXs
Funding Source:	Hyundai Hope on Wheels, Young Investigator Award
Role:	PI

Date:	2018 - 2020
Title:	Young Investigator Award, Pre-clinical drug testing through an in vivo micro-scale implantable device in Ewing sarcoma PDXs
Funding Source:	Hyundai Hope on Wheels
Role:	PI

Date:	2015 - 2016
Title:	Cancer Free Kids-Pediatric Cancer Research
Funding Source:	NAMPT in Neuroblastoma
Role:	Co-PI

Selected Publications

Peer-Reviewed Articles

Loghavi S, Farhat A, Jamison TJ, El Hajjar G, Bataller A, Wang SA, Wang W, Tang G, Quesada AE, Bazinet A, Cuglievan B, DiNardo CD, Montalban-Bravo G, Takahashi K, Short NJ, Abbas HA, Kadia T, Ravandi F, Daver N, Jabbour E, Borthakur G, Andreeff M, Medeiros LJ, Kantarjian HM, Issa GC. Immunophenotypic changes following menin inhibition in acute myeloid leukemia. Leukemia, 2026. e-Pub 2026. PMID: 41814014.
Catueno S, Frost M, Cuglievan B, Gibson A, McCall D, Nunez C, Roth M, Malpica L, Garcia MB. Uncommon Presentation and Therapeutic Strategies in Pediatric Relapsed/Refractory ALK-Positive ALCL. J Pediatr Hematol Oncol, 2026. e-Pub 2026. PMID: 41818168.
Fiskus W, Mill CP, Issa GC, Piel J, Collins MP, Hentemann M, Cuglievan B, Hou H, Jain A, Malovannaya A, Kadia TM, Daver NG, Sasaki K, Takahashi K, Hammond D, Senapati J, Loghavi S, Flores L, Su X, DiNardo CD, Bhalla KN. Overcoming Menin inhibitor resistance in AML cells with combinations including BET proteins and dual BRG1/BRM inhibitor. Blood, 2026. e-Pub 2026. PMID: 41734382.
Singh A, Daver N, Loghavi S, Kadia T, Ravandi F, DiNardo C, Borthakur G, Pierce S, Futreal A, Aung PP, Cuglievan B, Jain N, Jabbour E, Garcia-Manero G, Konopleva M, Qazilbash M, Pemmaraju N. Ten-year long-term survivors of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Leuk Lymphoma:1-4, 2026. e-Pub 2026. PMID: 41711093.
Garcia MB, Wang B, Sheikh I, El Hajjar G, McCall D, Nunez C, Gibson A, Lorenzi PL, Issa GC, Cuglievan B, Abbas HA. High-throughput proteomic profiling to evaluate differentiation syndrome with menin inhibition. Mol Cell Proteomics:101522, 2026. e-Pub 2026. PMID: 41621809.
Okeleji O, McCall D, Cuglievan B, Gibson A, Petropoulos D, Tewari P, Connors J, Sheikh IN. Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab. Br J Haematol, 2026. e-Pub 2026. PMID: 41582414.
Fiskus W, Mill CP, Piel J, Collins M, Hentemann M, Cuglievan B, Birdwell CE, Das K, Davis JA, Hou H, Jain A, Malovannaya A, Flores LB, Kadia TM, Daver N, Sasaki K, Takahashi K, Hammond D, Wang J, Loghavi S, Su X, DiNardo CD, Delwel R, Bhalla KN. Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML. Hemasphere 10(1):e70289, 2026. e-Pub 2026. PMID: 41551728.
Raj R, Catueno S, Gibson A, McCall D, Garcia MB, Nunez C, Roth M, Sasaki K, Tewari P, Issa GC, Farhat A, Connors J, Sheikh I, Nishida Y, Yi JS, Stevens AM, Bataller A, Bhalla K, Petropoulos D, Daver N, Kadia T, Cuglievan B, DiNardo CD. FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML. Blood 146(21):2608-2611, 2025. e-Pub 2025. PMID: 40971491.
Catueno, S, Ramakrishnan, R, Elitzur, S, Garcia, MB, McCall, DC, Nunez, CA, Roth, M, Ferrajoli, A, Cuglievan, B, Gibson, A. Lymphoid Malignancies in Ataxia–Telangiectasia. Pediatric Blood and Cancer 72(9), 2025. e-Pub 2025. PMID: 40605148.
Berkman, AM, Andersen, C, Puthenpura, V, Short, NJ, Merriman, K, Swaminathan, M, Cuglievan, B, McCall, DC, DiNardo, C, Nunez, CA, Jain, N, Kadia, TM, Issa, GC, Gibson, A, Garcia, MB, Andrew Livingston, J, Parsons, SK, Hildebrandt, MA, Roth, M. Risk of early death after acute leukemia diagnosis among adolescents and young adults. JNCI Cancer Spectrum 9(4), 2025. e-Pub 2025. PMID: 40579211.
Elgehiny, A, Hsu, A, McCall, DC, Gibson, A, Cuglievan, B, Nunez, CA, Garcia, MB, Castellanos, LE, Funck, A, Razvi, S. Severe Hypertriglyceridemia Secondary to Long-acting Asparaginase in Pediatric Patients With Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology 47(6):e215-e221, 2025. e-Pub 2025. PMID: 40560745.
Corrigan KL, Berkman AM, Gunther J, Andersen CR, Wu S, Gibson A, Cuglievan B, Garcia MB, Manzar G, Fang P, De B, Ahmed S, Nunez C, Hildebrandt MAT, McCall DC, Parsons SK, Roth ME. Trends in Radiation Use from 2004-2020 Among Adolescents and Young Adults with Hodgkin Lymphoma. Cancer Epidemiol Biomarkers Prev 34(9):1483-1491, 2025. e-Pub 2025. PMID: 40488452.
Wahba A, Catueno S, Na K, Dickson S, Stevens A, Cuglievan B, Redell MS. Characteristics and outcomes of newly diagnosed pediatric acute myeloid leukemia patients who were removed from standard regimens and received alternative therapy. Haematologica 110(11):2834-2838, 2025. e-Pub 2025. PMID: 40400478.
Ly CP, Veletic I, Pacheco CD, Dasdemir E, Jelloul FZ, Ferri-Borgogno S, Basi AV, Gomez JA, Root JL, Reville PK, Jindal S, Basu S, Sharma P, Quesada AE, Bueso-Ramos C, Manshouri T, Cuglievan B, Garcia M, Burks JK, Abbas HA. Multimodal spatial proteomic profiling in acute myeloid leukemia. NPJ Precis Oncol 9(1):148, 2025. e-Pub 2025. PMID: 40394148.
Cruz CA, Rodriguez ER, Thawani M, Mazer M, Hayhurst M, Swanson M, Romero A, Livingston JA, Aune G, Eshelman-Kent D, Cuglievan B, Roth ME, Ahmed S, Albritton K, Hildebrandt MAT. Differences in time to treatment and impact on overall survival in adolescents and young adults with Hodgkin lymphoma. Leuk Lymphoma:1-7, 2025. e-Pub 2025. PMID: 40337837.
He J, Munir F, Ayerbe C, Dickson S, Catueno S, Cuglievan B, Gibson A, McCall D, Nunez C, Roth M, Tewari P, Garcia MB, Rodriguez N, Cortes J. Managing and Preventing Hypofibrinogenemia in Pediatric and AYA Leukemia Patients: Insights From MD Anderson Cancer Center. J Pediatr Hematol Oncol 47(5):235-241, 2025. e-Pub 2025. PMID: 40306291.
Yi JS, Cuglievan B. Acute Leukemia in the Crosshairs: First-in-Class Menin Inhibitor Approval for Adults and Children. Pediatr Blood Cancer 72(6):e31657, 2025. e-Pub 2025. PMID: 40103277.
Fiskus W, Mill CP, Piel J, Collins M, Hentemann M, Cuglievan B, Birdwell CE, Das K, Hou H, Davis JA, Jain A, Malovannaya A, Kadia TM, Daver N, Sasaki K, Takahashi K, Hammond D, Reville PK, Flores LB, Loghavi S, Su X, DiNardo CD, Bhalla KN. Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. Blood Cancer J 15(1):40, 2025. e-Pub 2025. PMID: 40089460.
Okeleji O, McCall D, Gibson A, Garcia MB, Nunez C, Roth ME, Connors JS, Petropoulos D, Tewari P, Cuglievan B, Sheikh IN. MENIN MAINTENANCE THERAPY FOR ACUTE LEUKEMIA. Blood Adv 9(8):1988-1990, 2025. e-Pub 2025. PMID: 39993239.
Cuglievan B, Subbiah V. Transforming paediatric AML trials: from failing one-size-fits-all methods to precision oncology. Nat Rev Clin Oncol 22(3):155-156, 2025. e-Pub 2025. PMID: 39870759.
Roth, M, Andersen, C, Berkman, AM, Siegel, SE, Cuglievan, B, Livingston, JA, Hildebrandt, MA, Estrada, J, Bleyer, A. Improved survival and decreased cancer deaths in young adults with cancer after passage of the Affordable Care Act Dependent Coverage Expansion. Cancer 131(1), 2025. e-Pub 2025. PMID: 39370757.
Roth, M, Andersen, C, Berkman, AM, Siegel, SE, Cuglievan, B, Livingston, JA, Hildebrandt, MA, Estrada, J, Bleyer, A. Improved survival and decreased cancer deaths in young adults with cancer after passage of the Affordable Care Act Dependent Coverage Expansion. Cancer 131(1), 2025. e-Pub 2025. PMID: 39370757.
Issa GC, Aldoss I, Thirman MJ, DiPersio J, Arellano M, Blachly JS, Mannis GN, Perl A, Dickens DS, McMahon CM, Traer E, Zwaan CM, Grove CS, Stone R, Shami PJ, Mantzaris I, Greenwood M, Shukla N, Cuglievan B, Kovacsovics T, Gu Y, Bagley RG, Madigan K, Chudnovsky Y, Nguyen HV, McNeer N, Stein EM. Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J Clin Oncol 43(1):75-84, 2025. e-Pub 2025. PMID: 39121437.
Kahn, AR, Davis, ES, Dai, C, Caudill, CV, Martinez, I, Brackett, J, Sharma, A, Schwalm, C, Kebede, A, Dickens, DS, Richman, J, Colace, S, Araya, B, Bhatia, S, Wolfson, JA, Levine, J, Johnston, E, Aftandilian, C, Agrawal, AK, DeAngulo, G, Aristizabal, P, Bailey, K, Bardwell, JK, Becton, DL, Bemrich-Stolz, C, Boal, LH, Boston, CW, Bradfield, SM, Caywood, EH, Cohn, SM, Colace, S, Coven, SL, Cramer, SL, Cuglievan, B, Dargart, JL, Daghistani, D, Dhir, A, Dickens, DS, Dumitriu, A, Eslin, D, Esquilin, JM, Feinberg, S, Ferdjallah, A, Fernández, KS, Fixler, J, Foley, J, Gampel, BH, Glasser, CL, Goodman, JF, Gotesman, M. COVID-19 Disease in Children With ALL Receiving Maintenance Therapy. JCO Oncology Practice 20(12):1655-1662, 2024. e-Pub 2024. PMID: 39159420.
Gibson, A, Dickson, S, McCall, DC, Garcia, M, Connors, JS, He, J, Roth, M, Nunez, CA, Cuglievan, B. Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia. Pediatric Blood and Cancer 71(11), 2024. e-Pub 2024. PMID: 39152634.
McCall, DC, Alqahtani, S, Budak, M, Sheikh, IN, Fan, AE, Ramakrishnan, R, Nunez, CA, Roth, M, Garcia, M, Gibson, A, Daver, N, Garces, S, Short, NJ, Issa, GC, Ravandi-Kashani, F, DiNardo, C, Montalban Bravo, G, Garcia-Manero, G, Cuglievan, B, Kadia, TM. Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients. Cancers 16(22), 2024. e-Pub 2024. PMID: 39594839.
McCall, DC, Abuasab, T, Rodriguez-Sevilla, JJ, Mohamed, SF, Patnaik, A, Devireddy, K, Arani, N, Sheikh, IN, Jamshidi, R, Gibson, A, Roth, M, Nunez, CA, Garcia, M, Chien, KS, Loghavi, S, Pierce, S, Sasaki, K, Issa, GC, Cuglievan, B, Kantarjian, H, Garcia-Manero, G. Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms. Leukemia Research 144, 2024. e-Pub 2024. PMID: 39178611.
Rodriguez, ER, Tonn, T, Jafry, MZ, Ahmed, S, Cuglievan, B, Livingston, JA, Flowers, CR, Aune, GJ, Albritton, KH, Roth, M, Xiao, Q, Hildebrandt, MA. Neighborhood-level social determinants of health burden among adolescent and young adult cancer patients and impact on overall survival. JNCI Cancer Spectrum 8(4), 2024. e-Pub 2024. PMID: 39051679.
Lucas, BJ, Connors, JS, Wang, H, Conneely, S, Cuglievan, B, Garcia, M, Rau, R. Observation and Management of Juvenile Myelomonocytic Leukemia and Noonan Syndrome-Associated Myeloproliferative Disorder. Cancers 16(15), 2024. e-Pub 2024. PMID: 39123476.
Sarkar S, Rav E, Stitzlein L, Gibson A, McCall D, Nunez C, Roth M, Ragoonanan D, Connors J, Herzog CE, Cuglievan B, Garcia MB. Palbociclib and chemotherapy followed by blinatumomab consolidation to CAR-T cell therapy in KMT2A-rearranged, therapy-related acute lymphoblastic leukemia. Pediatr Blood Cancer 71(6):e30964, 2024. e-Pub 2024. PMID: 38514796.
Gibson A, Nunez C, Robusto L, Kammerer B, Garcia M, Roth M, Sheth R, Tewari P, Hittle A, Toepfer L, Torres R, Short NJ, Jabbour E, Jain N, Cuglievan B, McCall D. Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Haematologica 109(9):3042-3047, 2024. e-Pub 2024. PMID: 38779719.
Cuglievan B. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor. Blood 143(20):2059-2072, 2024. e-Pub 2024. PMID: 38437498.
Wolfson JA, Davis ES, Saha A, Martinez I, McCall D, Kothari P, Brackett J, Dickens DS, Kahn AR, Schwalm C, Sharma A, Richman J, Cuglievan B, Bhatia S, Dai C, Levine JM, Johnston EE. Adolescents and young adults (AYA) with cancer: the clinical course of COVID-19 infections. J Natl Cancer Inst 116(8):1366-1373, 2024. e-Pub 2024. PMID: 38627241.
Deng, Q, Lakra, P, Gou, P, Yang, H, Meydan, C, Teater, M, Chin, CR, Zhang, W, Dinh, T, Hussein, U, Li, X, Rojas, E, Liu, W, Reville, PK, Kizhakeyil, A, Barisic, D, Parsons, S, Wilson, A, Henderson, J, Scull, B, Gurumurthy, CB, Vega Vazquez, F, Chadburn, A, Cuglievan, B, El-Mallawany, NK, Allen, CE, Mason, CE, Melnick, A, Green, M. SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. Cancer cell 42(4):605-622.e11, 2024. e-Pub 2024. PMID: 38458188.
Short, NJ, Jabbour, EJ, Jamison, T, Paul, S, Cuglievan, B, McCall, DC, Gibson, A, Jain, N, Haddad, FG, Nasr, L, Marx, K, Rausch, CR, Savoy, JM, Garris, R, Ravandi-Kashani, F, Kantarjian, HM. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 24(4):e168-e173, 2024. e-Pub 2024. PMID: 38212207.
Wang B, Reville PK, Yassouf MY, Jelloul FZ, Ly C, Desai PN, Wang Z, Borges P, Veletic I, Dasdemir E, Burks JK, Tang G, Guo S, Garza AI, Nasnas C, Vaughn NR, Baran N, Deng Q, Matthews J, Gunaratne PH, Antunes DA, Ekmekcioglu S, Sasaki K, Garcia MB, Cuglievan B, Hao D, Daver N, Green MR, Konopleva M, Futreal A, Post SM, Abbas HA. Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies. Nat Commun 15(1):1821, 2024. e-Pub 2024. PMID: 38418901.
Catueno S, Haddad F, Cuglievan B. The efficacy of homoharringtonine in pediatric acute myeloid leukemia: findings from the Chinese Children’s Leukemia Group-AML 2015 Study. Transl Pediatr 13(2):376-379, 2024. e-Pub 2024. PMID: 38455741.
Bataller A, Abuasab T, McCall D, Wang W, Cuglievan B, Issa GC, Jabbour E, Short N, DiNardo CD, Tang G, Garcia-Manero G, Kantarjian HM, Sasaki K. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineage-directed therapies. Haematologica 109(1):293-297, 2024. e-Pub 2023. PMID: 37646654.
Juul-Dam, KL, Shukla, N, Cooper, T, Cuglievan, B, Heidenreich, O, Kolb, EA, Rasouli, M, Hasle, H, Zwaan, CM. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression. European Journal of Medical Genetics 66(12), 2023. e-Pub 2023. PMID: 38174649.
Pasvolsky, O, Bassett Jr, R, Ghanem, S, Cuglievan, B, Tewari, P, Hosing, C, Srour, S, Ramdial, JL, Mahadeo, KM, Khazal, SJ, Petropoulos, D, Popat, UR, Qazilbash, MH, Kebriaei, P, Champlin, RE, Shpall, E, Nieto, Y. Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant. BMC cancer 23(1), 2023. e-Pub 2023. PMID: 38124057.
He, J, Garcia, MB, Connors, JS, Nunez, CA, Quesada, AE, Gibson, A, Roth, M, Cuglievan, B, Pemmaraju, N, McCall, DC. Frontline Hyper-CVAD Plus Venetoclax for Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm. Journal of Pediatric Hematology/Oncology 45(8):E1001-E1004, 2023. e-Pub 2023. PMID: 37661300.
. Down Syndrome with Acute Myeloid Leukemia in an Adolescent Male Successfully Treated with Low Dose Ara-C in Combination with Hypomethylating Agent. 65th Annual Meeting of the American-Society-of-Hematology (ASH) 142(1), 2023. e-Pub 2023.
Martin SD, Davis ES, Dai C, Boal LH, Araya B, Brackett J, Dickens D, Kahn A, Martinez I, Sharma A, Schwalm C, Aguayo-Hiraldo P, Bhatia S, Levine JM, Johnston EE, Wolfson JA, Case Consortium POC. Clinical Features and Risk Factors Associated With Multisystem Inflammatory Syndrome in Children With Cancer and COVID-19. JAMA Oncol 9(8):1108-1112, 2023. e-Pub 2023. PMID: 37166782.
Forlenza CJ, Rosenzweig J, Mauguen A, Buhtoiarov IN, Cuglievan B, Dave H, Deyell R, Flerlage JE, Franklin ARK, Krajewski J, Leger KJ, Marks LJ, Norris RE, Pacheco M, Willen FK, Yan AP, Harker-Murray P, Giulino-Roth L. Brentuximab Vedotin Following Autologous Transplantation in Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma. Blood Adv 7(13):3225-3231, 2023. e-Pub 2023. PMID: 36897253.
Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, Daver NG, DiNardo CD, Jabbour EJ, Kadia TM, Borthakur G, Garcia-Manero G, Konopleva MY, Andreeff M, Ravandi-Kashani F, Sasaki K, Issa GC. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. Cancer 129(12):1856-1865, 2023. e-Pub 2023. PMID: 36892949.
Rav ES, Wahba A, Patnaik A, Toruner G, Hittle A, Toepfer L, Roth M, Cuglievan B, Nunez C, McCall D. A balancing act: Blinatumomab use in a rare occurrence of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia in an adolescent patient with Down syndrome. Pediatr Blood Cancer 70(5):e30191, 2023. e-Pub 2023. PMID: 36602024.
Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature 615(7954):920-924, 2023. e-Pub 2023. PMID: 36922593.
Munir, F, He, J, Connors, JS, Garcia, M, Gibson, A, McCall, DC, Nunez, CA, Dinh, CN, Robusto, L, Roth, M, Khazal, SJ, Tewari, P, Cuglievan, B. Translational advances in the treatment of childhood acute lymphoblastic leukemia: narrative review of current and emerging molecular and immunotherapies. Translational Pediatrics 12(3):487-502, 2023. e-Pub 2023. PMID: 37035397.
Trabal A, Gibson A, He J, McCall D, Roth M, Nuñez C, Garcia M, Buzbee M, Toepfer L, Bidikian A, Daver N, Kadia T, Short NJ, Issa GC, Ravandi F, DiNardo CD, Montalban Bravo G, Garces S, Marcogliese A, Paek H, Dreyer Z, Brackett J, Redell M, Yi J, Garcia-Manero G, Konopleva M, Stevens A, Cuglievan B. Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience. Cancers (Basel) 15(7), 2023. e-Pub 2023. PMID: 37046645.
Pagano L, Zinzani PL, Pileri S, Quaglino P, Cuglievan B, Berti E, Pemmaraju N, Onida F, Willemze R, Orfao A, Barosi G. Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper From an Ad Hoc International Expert Panel. Hemasphere 7(3):e841, 2023. e-Pub 2023. PMID: 36844178.
Pemmaraju N, Kantarjian HM, Sweet KL, Wang ES, Senapati J, Wilson NR, Konopleva MY, Frankel AE, Gupta V, Mesa RA, Ulrickson ML, Gorak E, Bhatia S, Budak-Alpdogan T, Mason JR, Garcia-Romero MT, Lopez-Santiago NC, Cesarman-Maus G, Vachhani P, Lee S, Bhatt VR, Blum W, Walter RB, Bixby D, Gojo I, Duvic M, Rampal RK, de Lima M, Foran JM, Fathi AT, Hall A, Jacoby MA, Lancet JE, Mannis GN, Stein AS, Mims AS, Rizzieri D, Olin RL, Perl AE, Schiller GJ, Shami PJ, Stone RM, Strickland S, Wieduwilt MJ, Daver NG, Ravandi F, Vasu S, Guzman ML, Roboz GJ, Khoury JD, Qazilbash MH, Aung P, Cuglievan B, Madanat YF, Kharfan-Dabaja MA, Pawlowska AB, Taylor J, Tallman MS, Dhakal P, Lane AA. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: Position on Standards of Care and Areas of Need. Blood 141(6):567-578, 2023. e-Pub 2022. PMID: 36399715.
Nieto Y, Pasvolsky O, Bassett R, Ghanem S, Cuglievan B, Tewari P, Hosing C, Sr S, Ramdial J, Mahadeo K, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall E. Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant. Res Sq, 2023. e-Pub 2023. PMID: 36798261.
McCall D, Jabbour E, Roth M, Nunez C, |Cuglievan B. Mini-hyper CVD + CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric B-acute lymphoblastic leukemia. Pediatr Blood Cancer 70(1):e29939, 2023. e-Pub 2022. PMID: 36031729.
Garces S, Rudzki Z, Yin CC, Miranda RN, Medina AM, Sriganeshan V, Cuglievan B, Li S, Xu J, Jelloul F, Khoury JD, Thakral B, Tang G, Garces JC, Medeiros LJ. MUM1/IRF4 is Highly Expressed in Dermatopathic Lymphadenopathy: Potential Utility in Diagnosis and Differential Diagnosis. Am J Surg Pathol 46(11):1514-1523, 2022. e-Pub 2022. PMID: 35877199.
Pemmaraju N, Cuglievan B, Lasky J, Kheradpour A, Hijiya N, Stein AS, Meshinchi S, Mullen C, Angelucci E, Vinti L, Mughal TI, Pawlowska A. AML-392 Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm in Pediatric Patients With Tagraxofusp, a CD123-Targeted Therapy. Clin Lymphoma Myeloma Leuk 22 Suppl 2(2022):S244-S245, 2022. e-Pub 2022. PMID: 36163828.
Qiu L, Nunez CA, Tang G, Cuglievan B, Issa GC, Wang SA, Medeiros LJ, Thakral B. A rare case of acute megakaryoblastic leukemia with t(11;17)(q23;q21) and KMT2A::MLLT6 fusion. Ann Hematol 101(7):1579-1581, 2022. e-Pub 2022. PMID: 35091795.
Berkman AM, Andersen CR, Cuglievan B, McCall DC, Lupo PJ, Parsons SK, DiNardo CD, Short NJ, Jain N, Kadia TM, Livingston JA, Roth ME. Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis. Cancer Epidemiol Biomarkers Prev 31(6):1176-1184, 2022. e-Pub 2022. PMID: 35553621.
Lamhamedi-Cherradi SE, Maitituoheti M, Menegaz BA, Krishnan S, Vetter AM, Camacho P, Wu CC, Beird HC, Porter RW, Ingram DR, Ramamoorthy V, Mohiuddin S, McCall D, Truong DD, Cuglievan B, Futreal PA, Velasco AR, Anvar NE, Utama B, Titus M, Lazar AJ, Wang WL, Rodriguez-Aguayo C, Ratan R, Livingston JA, Rai K, MacLeod AR, Daw NC, Hayes-Jordan A, Ludwig JA. The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma. Nat Commun 13(1):3057, 2022. e-Pub 2022. PMID: 35650195.
Nieto Y, Gruschkus S, Valdez BC, Jones RB, Anderlini P, Hosing C, Popat U, Qazilbash M, Kebriaei P, Alousi A, Saini N, Srour S, Rezvani K, Ramdial J, Barnett M, Gulbis A, Shigle TL, Ahmed S, Iyer S, Lee H, Nair R, Parmar S, Steiner R, Dabaja B, Pinnix C, Gunther J, Cuglievan B, Mahadeo K, Khazal S, Chuang H, Champlin R, Shpall EJ, Andersson BS. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica 107(4):899-908, 2022. e-Pub 2021. PMID: 33951890.
Molina ER, Chim LK, Lamhamedi-Cherradi SE, Mohiuddin S, McCall D, Cuglievan B, Krishnan S, Porter RW, Ingram DR, Wang WL, Lazar AJ, Scott DW, Truong DD, Daw NC, Ludwig JA, Mikos AG. Correlation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patients. Oncotarget 13(1):521-533, 2022. e-Pub 2022. PMID: 35284040.
Garces S, Medeiros LJ, Marques-Piubelli ML, Coelho Siqueira SA, Miranda RN, Cuglievan B, Sriganeshan V, Medina AM, Garces JC, Saluja K, Bhattacharjee MB, Khoury JD, Li S, Xu J, Jelloul FZ, Thakral B, Cameron Yin C. Cyclin D1 expression in Rosai-Dorfman disease: a near-constant finding that is not invariably associated with mitogen-activated protein kinase/extracellular signal-regulated kinase pathway activation. Hum Pathol 121:36-45, 2022. e-Pub 2022. PMID: 34995673.
Sheikh I, Nunez C, McCall D, Roth M, Cuglievan B. Programmed Cell Death Protein Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation in an Adolescent Patient. Pediatr Blood Cancer 69(3):e29390, 2022. e-Pub 2022. PMID: 35077016.
Roth M, Berkman A, Andersen CR, Cuglievan B, Andrew Livingston J, Hildebrandt M, Bleyer A. Improved Survival of Young Adults with Cancer Following the Passage of the Affordable Care Act. Oncologist 27(2):135-143, 2022. e-Pub 2022. PMID: 35641206.
Cuglievan B, McCall D, Robusto L, Mireles ME, Gettys SC. Current and emerging pharmacotherapy for the treatment of childhood acute myeloid leukemia. Expert Opin Pharmacother 23(17):1915-1925, 2022. e-Pub 2022. PMID: 36346029.
Ragoonanan D, Bhar S, Mohan G, Beltramo F, Khazal SJ, Hurley C, Andersen C, Margossian S, Neelapu SS, Shpall E, Gutierrez C, Tewari P, Shoberu B, Talleur A, McCall D, Nunez C, Cuglievan B, Tambaro FP, Petropoulos D, Abdel-Azim H, Mahadeo KM. A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy. Front Oncol 12:1022901, 2022. e-Pub 2022. PMID: 36353531.
Vallejo FA, Sanchez A, Cuglievan B, Walters WM, De Angulo G, Vanni S, Graham RM. NAMPT Inhibition Induces Neuroblastoma Cell Death and Blocks Tumor Growth. Front Oncol 12:883318, 2022. e-Pub 2022. PMID: 35814452.
McCall D, Roth M, Mahadeo KM, Toepfer L, Nunez C, Short NJ, Daver NG, Kadia TM, DiNardo CD, Yi JS, Cuglievan B. Gilteritinib Combination Therapies in Pediatric Patients with FLT3 Mutated Acute Myeloid Leukemia. Blood Adv 5:5215-5219, 2021. e-Pub 2021. PMID: 34592761.
Gibson A, Trabal A, McCall D, Khazal S, Toepfer L, Bell DH, Roth M, Mahadeo KM, Nunez C, Short NJ, DiNardo C, Konopleva M, Issa GC, Ravandi F, Jain N, Borthakur G, Kantarjian HM, Jabbour E, Cuglievan B. Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers (Basel) 14(1), 2021. e-Pub 2021. PMID: 35008312.
Berkman AM, Andersen CR, Puthenpura V, Livingston JA, Ahmed S, Cuglievan B, Hildebrandt MAT, Roth ME. Disparities in the long-term survival of adolescent and young adult diffuse large B cell lymphoma survivors. Cancer Epidemiol 75:102044, 2021. e-Pub 2021. PMID: 34597882.
Wahba A, Cuglievan B. Central nervous system Langerhans cell histiocytosis and neurodegenerative syndrome responding to MEK inhibition. EJHaem 2(4):881-882, 2021. e-Pub 2021. PMID: 35845219.
Baig MU, Rytting M, Roth M, Morani AC, Nunez C, Lin P, Cuglievan B. Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma. J Pediatr Hematol Oncol 43(7):e991-e996, 2021. e-Pub 2021. PMID: 33480649.
Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, Short NJ, Haddad F, Tang Z, Patel KP, Cuglievan B, Daver N, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Kantarjian HM, Ravandi F. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J 11(9):162, 2021. e-Pub 2021. PMID: 34588432.
Berkman AM, Andersen CR, Puthenpura V, Livingston JA, Ahmed S, Cuglievan B, Hildebrandt MAT, Roth ME. Impact of Race, Ethnicity, and Socioeconomic Status over Time on the Long-term Survival of Adolescent and Young Adult Hodgkin Lymphoma Survivors. Cancer Epidemiol Biomarkers Prev 30(9):1717-1725, 2021. e-Pub 2021. PMID: 34244160.
Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Tejada FNH, Martin PL, Auletta J, Choi SW, Bajwa R, Garnes ND, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM. Author Correction: Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol 18(7):468, 2021. e-Pub 2021. PMID: 33731864.
Flerlage JE, Hiniker SM, Armenian S, Benya EC, Bobbey AJ, Chang V, Cooper S, Coulter DW, Cuglievan B, Hoppe BS, Isenalumhe L, Kelly K, Kersun L, Lamble AJ, Larrier NA, Magee J, Oduro K, Pacheco M, Price AP, Roberts KB, Smith CM, Sohani AR, Trovillion EM, Walling E, Xavier AC, Burns JL, Campbell M. Pediatric Hodgkin Lymphoma, Version 3.2021. J Natl Compr Canc Netw 19(6):733-754, 2021. e-Pub 2021. PMID: 34214968.
Cabrera TB, Wang W, Yedururi S, Slopis JM, Steiner RE, Rytting ME, Cuglievan B. Coincidental Expression of Classic Hodgkin Lymphoma and Neurofibromatosis Type I and Literature Review. J Pediatr Hematol Oncol 43(4):E535-E538, 2021. e-Pub 2020. PMID: 32366782.
Cuglievan B, Berkman A, Dibaj S, Wang J, Andersen CR, Livingston JA, Gill J, Bleyer A, Roth M. Impact of Lagtime, Health Insurance Type, and Income Status at Diagnosis on the Long-Term Survival of Adolescent and Young Adult Cancer Patients. J Adolesc Young Adult Oncol 10(2):164-174, 2021. e-Pub 2020. PMID: 32678703.
Kadipasaoglu C, Wahba A, Bhattacharjee MB, Cuglievan B, Fletcher SA. Hemorrhagic Giant Cell Tumor of the Occipital Skull Base: A Case Report and Literature Review. Cureus 13(3):e13832, 2021. e-Pub 2021. PMID: 33859893.
Strati P, Cheng PTM, Steiner RE, Alcedo Andrade PE, Feng L, Sano D, Rao VA, Singh P, Miranda R, Gunther JR, Pinnix CC, Dabaja BS, Cuglievan B, Xing K, Villa D, Skinnider B, Sehn LH, Connors JM, Nieto Y, Ahmed S, Lee HJ, Savage KJ. Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis. Br J Haematol 192(3):560-567, 2021. e-Pub 2021. PMID: 33517581.
Lamhamedi-Cherradi SE, Mohiuddin S, Mishra DK, Krishnan S, Velasco AR, Vetter AM, Pence K, McCall D, Truong DD, Cuglievan B, Menegaz BA, Utama B, Daw NC, Molina ER, Zielinski RJ, Livingston JA, Gorlick R, Mikos AG, Kim MP, Ludwig JA. Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. Cancer Gene Ther 28(12):1325-1338, 2021. e-Pub 2021. PMID: 33408328.
Davies K, Barth M, Armenian S, Audino AN, Barnette P, Cuglievan B, Ding H, Ford JB, Galardy PJ, Gardner R, Hanna R, Hayashi R, Kovach AE, Machnitz AJ, Maloney KW, Marks L, Page K, Reilly AF, Weinstein JL, Xavier AC, McMillian NR, Freedman-Cass DA. Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(8):1105-1123, 2020. e-Pub 2020. PMID: 32755986.
McCall D, Tewari P, Kass JDA, Cuglievan B. The Evolution of the Pediatric Hematology/Oncology Fellowship: What Does it Mean to be Productive?. J Pediatr Hematol Oncol 42(6):e544-e545, 2020. e-Pub 2020. PMID: 32032246.
Amin HM, Morani AC, Daw NC, Lamhamedi-Cherradi SE, Subbiah V, Menegaz BA, Vishwamitra D, Eskandari G, George B, Benjamin RS, Patel S, Song J, Lazar AJ, Wang WL, Kurzrock R, Pappo A, Anderson PM, Schwartz GK, Araujo D, Cuglievan B, Ratan R, McCall D, Mohiuddin S, Livingston JA, Molina ER, Naing A, Ludwig JA. IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. Cancers (Basel) 12(7):1-17, 2020. e-Pub 2020. PMID: 32630797.
Molina ER, Chim LK, Salazar MC, Koons GL, Menegaz BA, Ruiz-Velasco A, Lamhamedi-Cherradi SE, Vetter AM, Satish T, Cuglievan B, Smoak MM, Scott DW, Ludwig JA, Mikos AG. 3D Tissue-Engineered Tumor Model for Ewing's Sarcoma That Incorporates Bone-like ECM and Mineralization. ACS Biomater Sci Eng 6(1):539-552, 2020. e-Pub 2020. PMID: 33463239.
Subbiah V, Lamhamedi-Cherradi SE, Cuglievan B, Menegaz BA, Camacho P, Huh W, Ramamoorthy V, Anderson P, al E. Desmoplastic Small Round Cell Tumor: A Multidisciplinary Approach That Improves Patient Survival. Clinical Cancer Research, 2020. e-Pub 2020.
Cuglievan B, Subbiah V, Meric-Bernstam F, Herzog C. Response to mTOR-based therapy and incidental finding of Lynch syndrome in a patient with solid pseudopapillary neoplasm of the pancreas with AKT1_E17K mutation. JCO Precision Oncology, 2020. e-Pub 2020.
Molina ER, Chim LK, Salazar MC, Mehta SM, Menegaz BA, Lamhamedi-Cherradi SE, Satish T, Mohiuddin S, McCall D, Zaske AM, Cuglievan B, Lazar AJ, Scott DW, Grande-Allen JK, Ludwig JA, Mikos AG. Mechanically tunable coaxial electrospun models of YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma. Acta Biomater 100:38-51, 2019. e-Pub 2019. PMID: 31542501.
Puerto-Camacho P, Amaral AT, Lamhamedi-Cherradi SE, Menegaz BA, Castillo-Ecija H, Ordóñez JL, Domínguez S, Jordan-Perez C, Diaz-Martin J, Romero-Pérez L, Lopez-Alvarez M, Civantos-Jubera G, Robles-Frías MJ, Biscuola M, Ferrer C, Mora J, Cuglievan B, Schadler K, Seifert O, Kontermann R, Pfizenmaier K, Simón L, Fabre M, ÁM C, Ludwig JA, de Álava E. Preclinical efficacy of endoglin-targeting antibody-drug conjugates for the treatment of Ewing sarcoma. Clin Cancer Res 25(7):2228-2240, 2019. e-Pub 2019. PMID: 30420447.
Subbiah V, Lamhamedi-Cherradi SE, Cuglievan B, Menegaz BA, Camacho P, Huh W, Ramamoorthy V, Anderson PM, Pollock RE, Lev DC, Qiao W, McAleer MF, Benjamin RS, Patel S, Herzog CE, Daw NC, Feig BW, Lazar AJ, Hayes-Jordan A, Ludwig JA. Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. Clin Cancer Res 24(19):4865-4873, 2018. e-Pub 2018. PMID: 29871905.
Menegaz BA, Cuglievan B, Benson J, Camacho P, Lamhamedi-Cherradi SE, Leung CH, Warneke CL, Huh W, Subbiah V, Benjamin RS, Patel S, Daw N, Hayes-Jordan A, Ludwig JA. Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor. Oncologist 23(3):360-366, 2018. e-Pub 2018. PMID: 29212731.
Zapata CP, Cuglievan B, Zapata CM, Olavarrieta R, Raskin S, Desai K, De Angulo G. PET/CT versus bone marrow biopsy in the initial evaluation of bone marrow infiltration in various pediatric malignancies. Pediatr Blood Cancer 65(2), 2018. e-Pub 2018. PMID: 28901637.
Cuglievan B, Subbiah V, Wang H, Morani A, Meric-Bernstam F, Holla V, Herzog CE. Response to Mammalian Target of Rapamycin-Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With AKT1_E17K Mutation. JCO Precis Oncol 2(2):1-6, 2018. e-Pub 2018. PMID: 31650099.
Maher OM, Silva JG, Huh WW, Cuglievan B, DePombo A, Kebriaei P, Park M, Liu D, Tillman C, Tarek N, Cooper LJN, Tewari P. Etiologies and Impact of Readmission Rates in the First 180 Days After Hematopoietic Stem Cell Transplantation in Children, Adolescents, and Young Adults. J Pediatr Hematol Oncol 39(8):609-613, 2017. e-Pub 2017. PMID: 28859043.
Cuglievan B, Menegaz BA, Garces S, Rytting ME. Acute myeloid leukaemia masquerading as a primary CNS tumour. BMJ Case Rep 2017, 2017. e-Pub 2017. PMID: 28801332.
Cuglievan B, Menegaz BA, DePombo A, Morani AC, Miranda RN, Rytting M. A pediatric patient with glycogen storage disease type IA and Castleman disease. Pediatr Blood Cancer 64(8), 2017. e-Pub 2017. PMID: 28035790.
Lahiri S, Cuglievan B, Gutierrez JL, Pefkarou A. Successful conservative treatment of myocardial infarction in a teenager with MTHFR mutation. Int J Cardiol Heart Vasc 15:24-25, 2017. e-Pub 2017. PMID: 28616569.
Cuglievan B, Miranda RN. Kikuchi-Fujimoto disease. Blood 129(7):917, 2017. e-Pub 2017. PMID: 28209753.

Review Articles

Subbiah V, Othus M, Palma J, Cuglievan B, Kurzrock R. Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras. Am Soc Clin Oncol Educ Book 45(3):e100051, 2025. e-Pub 2025. PMID: 40228175.
McCall D, Catueno S, Ramakrishnan R, Tewari P, Sheikh I, Gibson A, Nunez CA, Garcia MB, Cuglievan B. Beyond Cellular Therapies: The Expanding Role of Antibody-Driven Immunotherapy in Pediatric Acute Lymphoblastic Leukemia. Acta Haematol 149(1):1-31, 2025. e-Pub 2025. PMID: 40324358.
Catueno S, Cuglievan B. Pediatric Lymphomas: Key Concepts and Clinical Approaches for Pediatricians. Pediatr Rev 46(2):78-90, 2025. e-Pub 2025. PMID: 39889786.
Cuglievan, B, Kantarjian, HM, Rubnitz, JE, Cooper, T, Zwaan, CM, Pollard, J, DiNardo, C, Kadia, TM, Guest, E, Short, NJ, McCall, DC, Daver, N, Nunez, CA, Haddad, FG, Garcia, MB, Bhalla, K, Maiti, A, Catueno, S, Fiskus, WC, Carter, BZ, Gibson, A, Roth, M, Khazal, SJ, Tewari, P, Abbas, HA, Bourgeois, W, Andreeff, M, Shukla, N, Truong, D, Connors, JS, Ludwig, JA, Stutterheim, J, Salzer, E, Juul-Dam, KL, Sasaki, K, Mahadeo, KM, Tasian, SK, Borthakur, G, Dickson, S, Jain, N, Jabbour, EJ, Meshinchi, S, Garcia-Manero, G, Ravandi, F, Stein, EM, Kolb, EA, Issa, GC. Menin inhibitors in pediatric acute leukemia. Leukemia 38(10):2073-2084, 2024. e-Pub 2024. PMID: 39179671.
He, J, Munir, F, Catueno, S, Connors, JS, Gibson, A, Robusto, L, McCall, DC, Nunez, CA, Roth, M, Tewari, P, Garces, S, Cuglievan, B, Garcia, MB. Biological Markers of High-Risk Childhood Acute Lymphoblastic Leukemia. Cancers 16(5), 2024. e-Pub 2024. PMID: 38473221.
Cuglievan B, Connors J, He J, Khazal S, Yedururi S, Dai J, Garces S, Quesada AE, Roth M, Garcia M, McCall D, Gibson A, Ragoonanan D, Petropoulos D, Tewari P, Nunez C, Mahadeo KM, Tasian SK, Lamble AJ, Pawlowska A, Hammond D, Maiti A, Haddad FG, Senapati J, Daver N, Gangat N, Konopleva M, Meshinchi S, Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies. Leukemia 37(9):1767-1778, 2023. e-Pub 2023. PMID: 37452102.
Munir F, Hardit V, Sheikh IN, AlQahtani S, He J, Cuglievan B, Hosing C, Tewari P, Khazal S. Classical Hodgkin Lymphoma: From Past to Future-A Comprehensive Review of Pathophysiology and Therapeutic Advances. Int J Mol Sci 24(12), 2023. e-Pub 2023. PMID: 37373245.
Gibson A, Hernandez C, Tejada FNH, Kawedia J, Rytting M, Cuglievan B. Asparaginase-Associated Pancreatitis in Pediatric Patients with Acute Lymphoblastic Leukemia: Current Perspectives. Paediatr Drugs 23(5):457-463, 2021. e-Pub 2021. PMID: 34351604.
Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Hernandez Tejada FN, Martin PL, Auletta J, Choi SW, Bajwa R, Dailey Garnes N, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol 18(7):435-453, 2021. e-Pub 2021. PMID: 33608690.
Hernandez Tejada FN, Zamudio A, Marques-Piubelli ML, Cuglievan B, Harrison D. Advances in the Management of Pediatric Sarcomas. Curr Oncol Rep 23(1):3, 2020. e-Pub 2020. PMID: 33196879.

Abstracts

Khazaei S, Nair S, Ostermann L, Mizuno H, Mak PY, Carter B, Boettcher S, Ma L, Garcia M, Cuglievan B, Stevens AM, Andreeff M, Nishida Y. Protein degradation of MYC/GSPT1 combined with menin inhibition overcomes resistance to menin inhibition in KMT2A-rearranged Acute Myeloid Leukemia. 67th Annual Meeting of the American-Society-of-Hematology (ASH), 2025. e-Pub 2025.
Aldoss I, Issa GC, Thirman M, DiPersio J, Arellano M, Blachly JS, Mannis GN, Perl A, Dickens DS, McMahon CM, Traer E, Zwaan C, Grove C, Stone R, Shami PJ, Mantzaris I, Greenwood M, Shukla N, Cuglievan B, Gu Y, Bagley RG, Madigan K, Sunkaraneni S, Nguyen HV, McNeer N, Stein EM. Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal AUGMENT-101 Phase 2 Study. European Hematology Association 2024 Hybrid Congress. e-Pub 2024.
Pemmaraju N, Cuglievan B, Lasky J, Kheradpour A, Hijiya N, Stein AS, Meshinchi S, Mullen CA, Angelucci E, Vinti L, Mughal TI, Pawlowska AB. Efficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent/young adult patients. EJHaem 5(1):61-69, 2024. e-Pub 2024. PMID: 38406504.
Cuglievan B. Clinical characteristics of acute leukemia with PICALM::MLLT10 fusion in adults. ASCO Abstract #442702 - 2024 ASCO Annual Meeting (May 31 - June 4, 2024). e-Pub 2024.
Issa GC, Cuglievan B, DiNardo CD, Short NJ, McCall D, Gibson A, Nunez C, Garcia MB, Roth M, Bidikian A, Pike A, Tan S, Kammerer B, Yilmaz M, Kadia TM, Pemmaraju N, Ohanian M, Daver N, Jabbour E, Borthakur G, Ravandi F, Garcia-Manero G, Andreeff M, Kantarjian HM. Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE). Blood 142(1), 2023. e-Pub 2023.
Hildebrandt M, Xiao Q, Flowers C, Tonn T, Jafry M, Ahmend S, Cuglievan B, Livingston J, Aune G, Albritton K, Roth M, Rodriguez E. Social Determinants of Health Burden among Adolescent and Young Adult Cancer Patients and Impact on Overall Survival 41(16_suppl), 2023. e-Pub 2023.
Chan KH, Ramdial J, Hosing C, Srour S, Alousi A, Kebriaei P, Popat U, Qazilbash M, Ahmed S, Iyer S, Lee H, Nair R, Steiner R, Strati P, Dabaja B, Fang P, Gunther J, Pinnix C, Wu S, Cuglievan B, Mahadeo K, Champlin R, Shpall EJ, Nieto Y. Outcome of Patients with Classical Hodgkin Lymphoma (cHL) Relapsing After an Autologous Stem-Cell Transplant (ASCT), 2022. e-Pub 2022.
Issa G, Cuglievan B, Stein E, Arellano M, Zucenka A, Khera N, Stone R, Thirman M, Dipersio J, Gu Y, Bagley R, Tamang D, Dishman K, Meyers M, Madigan K, McNeer N, Aldoss I. Outcomes after transplant in relapsed/refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia patients achieving remissions after menin inhibition: SNDX-5613 (revumenib) Ph1 experience, 2022. e-Pub 2022.
Cuglievan, B, McCall, D. The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy For DSRCT, 2022. e-Pub 2022.
Deng Q, PhD, Meydan C, PhD, Lakra P, PhD, Barisic D, Chin CR, Rojas-Neira E, Ravenmehr V, Henderson J, PhD, Gou P, El-Mallawany NK, MD, Allen C, MD, PhD, Cuglievan B, MD, Vega F, MD, PhD, Mason CE, PhD, AriMelnick, MD and Michael R Green MD, PhD. Smarca4 (Brg1) Controls Germinal Center B-Cell Development and Is a Haploinsufficient Tumor Suppressor in Lymphoma, 2022. e-Pub 2022.
Pasvolsky O, , , Bassett RL, Ghanem S, Cuglievan B, Tewari P, Hosing C, Srour S, Ramdial J, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall EJ, Nieto Y. Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing First Autologous Hematopoietic Stem Cell Transplant, 2022. e-Pub 2022.
Issa GC, MD, Aldoss I, MD, DiPersio J, MD PhD MD, Cuglievan B, MD, Stone R, MD, Arellano M, MD, Thirman M, MD, Patel M, MD, Dickens D, MD, Shukla N, MD, Bagley RG, MA, Meyers ML, MD PhD MD, Madigan K, MD, Ordentlich P, PhD, Gu Y, PhD, Smith S, PhD, McGeehan G, PD, Stein AE, MD. The Menin Inhibitor SNDX-5613 (revumenib) leads to Durable Responses in Patients with KMT2A-rearranged or NPM1 mutant AML: Results of a Phase 1 study, 2022. e-Pub 2022.
Nguyen D, Ning J, Qiao W, Sasaki K, Kantarjian HM, Short NJ, Cuglievan B, Daver NG, Dinardo CD, Jabbour E, Kadia TM, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Ravandi F, Issa GC. Acute myeloid leukemia with KMT2Ar and association with risk of bleeding and early mortality, 2022. e-Pub 2022.
Pemmaraju N, Cuglievan B, Lasky J, Kheradpour A, Hijiya N, Stein AS, Meshinchi S, Mullen C, Angelucci E, Vinti L, Mughal TI, Pawlowska A. Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in Pediatric Patients with Tagraxofusp, a CD123-Targeted Therapy. "EHA", 2022. e-Pub 2022.
Jain T, Sheikh I, Sarkar S, Gibson A, Trabal A, Toepfer L, Bell D, McCall D, Nunez C, Roth M, Cuglievan B. Risk Factors For 3rd Or Greater Relapses In AYA Patients With Classical Hodgkin Lymphoma, 2021. e-Pub 2021.
Ragoonanan D, Harden A, Elgehiny A, Nunez C, Roth M, McCall D, Cuglievan B, Tewari P, Petropoulos D, Mahadeo K, Khazal S. Allogeneic Hematopoietic Stem Cell Transplant may Improve Survival in Pediatric and Adolescent and Young Adult Patients with Acute Myeloid Leukemia and DNMT3A Mutations, 2021. e-Pub 2021.
Trabal A, Gibson A, McCall D, Roth M, Nuñez C, Mahadeo K, Khazal S, Buzbee M, Toepfer L, Daver N, Kadia T, Short N, Issa G, Ravandi F, Dinardo C, Garces S, Marcogliese A, Paek H, Dreyer Z, Brackett J, Redell M, Yi J, Garcia-Manero G, Kantarjian H, Konopleva M, Stevens A, Cuglievan AB. Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Collaboration, 2021. e-Pub 2021.
et al FC. Brentuximab Vedotin As Consolidation Therapy Following Autologous Stem Cell Transplantation in Children and Adolescents with Relapsed/Refractory Hodgkin Lymphoma, 2021. e-Pub 2021.
Wahba A, Cuglievan B. Giant Cell Tumor Of The Occipital Bone: A Case Report And Review Of Literature, 2021. e-Pub 2021.
Sheikh I, Sarkar S, Jain T, Gibson A, Trabal A, Toepfer L, Bell D, McCall D, Nunez C, Roth M, Cuglievan B. Nodular Lymphocyte Predmoinant Hodgkin Lymphoma In Aya, 2021. e-Pub 2021.
Wahba A, Toepfer L, Roth M, Mccall D, Subbiah V, Khatua S, Cuglievan B. CNS and Neurodegenerative Syndrome Responding To MEK Inhibitor After Being Refractory, 2021. e-Pub 2021.
Gibson A, Trabal A, Mccall D, Toepfer L, Roth M, Mahadeo K, Cuglievan B. Venetoclax For Acute Myeloid Leukemia In Pediatric Patients: The Md Anderson Cancer Center Experience, 2021. e-Pub 2021.
Sheikh I, Sarkar S, Jain T, Gibson A, Trabal A, Toepfer L, Bell D, McCall D, Nunez C, Roth M, Cuglievan B. AYA patients with Mixed Cellularity Classical Hodgkin Lymphoma, 2021. e-Pub 2021.
Wahba A, Toepfer L, Bell D, Roth M, McCall D, Nunez C, Cuglievan B. Synchronous Leukemia and Ependymoma In A Pediatric Patient With No Genetic Predisposition, 2021. e-Pub 2021.
Sarkar S, Sheikh I, Jain T, Gibson A, Trabal A, Toepfer L, Bell D, McCall D, Roth M, Nunez C, Cuglievan B. Impact Of Body Mass Index (BMI) On Overall Relapse Of Classical Hodgkin Lymphoma, 2021. e-Pub 2021.
Gibson A, Trabal A, McCall D, Toepfer L, Roth M, Mahadeo K, Cuglievan B. Venetoclax For Acute Lymphoblastic Leukemia In Pediatric Patients, 2021. e-Pub 2021.
Pemmaraju N, Cuglievan B, Lasky J, Kheradpour A, Hijiya N, Stein AS, Meshinchi S, Mullen C, Angelucci E, Vinti L, Mughal TI, Pawlowska A. Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in Pediatric Patients with Tagraxofusp, a CD123-Targeted Therapy. "ASH". ASH, 2021. e-Pub 2021.
R E Steiner R, F Cramer F, P Singh P, M Becnel M, P Alcedo P, C Chin C, B Cuglievan B, P Strati P, S Ahmed S, F Samaniego F, J Gunther J, C Pinnix C, P Fang P, B Dabaja B, L Feng L, HJ Lee HJ. Brentuximab Vedotin with Chemotherapy for Advanced Stage Classical Hodgkin’s Lymphoma in a real world setting, 2020. e-Pub 2020.
McCall D, Ruiz Velasco A, Mohiuddin S, Lamhamedi-Cherradi SE, Krishnan S, Truong DD, Cuglievan B, Vetter A, Ludwig JA. Ewing Sarcoma Knockout Model and its Implication for Targeted Therapy, 2020. e-Pub 2020.
Mohiuddin S, Lamhamedi-Cherradi S, Mishra DK, Pence K, Krishnan S, Menegaz BA, David McCall MD, Velasco AR, Truong PhD DD, Cuglievan B, Vetter A, Molina ER, Kim MP, and Ludwig J. Role of EMT transcription factors in metastatic potential of osteosarcoma, 2019. e-Pub 2019.
Cuglievan B, Roth M, Triche L, Bell D, Chasen B, Nunez C, Rytting M. Response to venetoclax and decitabine in a patient with refractory T cell Lymphoblastic Lymphoma, 2019. e-Pub 2019.
19McCall D, Roszik J, Cuglievan B, Ludwig J, Zarzour M, Gill J, Livingston A, Subbiah V. EWS-fusion partners in sarcoma as revealed by "real world" genomic sequencing: clinical implications, 2019. e-Pub 2019.
Menegaz BA, Lamhamedi-Cherradi SE, Cuglievan B, Camacho P, Kim Y, Macleod R, Hayes-Jordan A, Ludwig JA. Preclinical Efficacy of Androgen Receptor-Based Anti-Sense Therapy for the Treatment of Desmoplastic Small Round Cell Tumor, 2018. e-Pub 2018.
Menegaz BA, Lamhamedi-Cherradi SE, Cuglievan B, Kim Y, Macleod R, Hayes-Jordan A, Ludwig JA. Preclinical Efficacy of Targeting EWSR1 In Ewing Sarcoma and Desmoplastic Small Round Cell Tumors, 2018. e-Pub 2018.
Menegaz BA, Cuglievan B, Admane P, Yang F, Dimiter D, Landesman Y, Lamhamedi-Cherradi SE, and Ludwig JA. New Synergistic mTOR-based combinations for the treatment of Ewing sarcoma, 2018. e-Pub 2018.
Amin H, Morani A, Daw N, Lamhamedi-Cherradi S, Subbiah V, Menegaz BA, Vishwamitra D, Eskandari G, George B, Benjamin R, Patel S, Song J, Lazar A, Wang W, Kurzrock R, Pappo A, Anderson P, Schwartz G, Araujo D, Cuglievan B, Naing A, Ratan R, Livingston A, Ludwig, JA. Igf-1r/Mtor Targeted Therapy For Ewing Sarcoma: A Meta-Analysis Of Five Igf-1r-Related Trials Matched To Proteomic And Radiologic Predictive Biomarkers, 2018. e-Pub 2018.
Lamhamedi-Cherradi S, Menegaz BA, Puerto-Camacho P, Amaral AT, Schadler K, Cuglievan, B, Domínguez S, Fabre M, Simon L, Alava ED, Ludwig JA. Preclinical efficacy of the endoglin-based antibody-drug conjugates OMTX703 for the treatment of Ewing sarcoma, 2017. e-Pub 2017.
Morrell M, Cuglievan B, Livinston JA, Huh W, and Ater J. Adolescent and young adult survivors of pediatric bone sarcomas and bone health, 2017. e-Pub 2017.
Nehme G, Cuglievan B, Camacho P, Menegaz BA, Coakley B, McAleer MF, Ludwig J, Hayes-Jordan A, Huh WW. Clinical characteristics of desmoplastic small round cell tumor in children 10 years of age and younger: an MD Anderson Cancer Center (MDACC) series, 2017. e-Pub 2017.
Menegaz BA, Cuglievan B, Benson J, Camacho P, Lahamedi-Cherradi SE, Leung CH, Warneke C, Huh W. Clinical activity of pazopanib in patients with advanced desmoplastic small round cell tumor, 2017. e-Pub 2017.
Ahlstrom, K, Cuglievan, B, Craven, P, Gatliff, M, Shephard, M, Tewari, P. Implementation of parameter transfusion orders for stem cell transplant recipients results in increased nursing autonomy, decreased transfusion delays, and improved patient care”, 2016. e-Pub 2016.
Cuglievan, B, Rytting, M. Castleman’s disease in a patient with Glycogen Storage Disease type 1a, 2016. e-Pub 2016.
Lahiri, S, Landeo, J, Cuglievan, B, Pefkarou, A. Myocardial Infarction in a teenage male with MTHFR gene mutation, 2016. e-Pub 2016.
Cuglievan B, DePombo A, Huh W, Harrison DJ, Hayes-Jordan A, Ludwig JA. Family history of cancer and its incidence on adult alveolar rhabdomyosarcoma (ARMS): an MD Anderson Cancer Center (MDACC) series, 2016. e-Pub 2016.
Zapata, C, Olavarrieta, R Raskin S, Zapata CA, Cuglievan, B, Desai, K, Angulo D, G. The role of PET/CT vs. Bone marrow biopsy in the initial evaluation of bone marrow infiltration in various pediatric solid tumors, 2015. e-Pub 2015.
Zapata C, Myrthil N, Cortesi-Gesten A, Cosme-Blanco W, Cuglievan B, Rodriguez G, De Angulo G, Vanni. Withaferin A as a novel differentiating agent for treatment of neuroblastoma, 2015. e-Pub 2015.
Zapata, C, Olavarrieta, R Raskin S, Zapata CA, Cuglievan, B, Desai, K, Angulo D, G. The role of PET/CT vs. Bone marrow biopsy in the initial evaluation of bone marrow infiltration in pediatric Non Hodgkin lymphoma. Fifth international Symposium on childhood, adolescent and young adult Non Hodgkin Lymphoma, 2015. e-Pub 2015.
Zhang B, Cuglievan B, Vanni S, Komotar RJ, Graham RM. Targeting glioblastoma stem cells with withaferin A, 2014. e-Pub 2014.
Cuglievan B, Hernandez F, De Angulo G, Vanni S, Graham R. The role of NAMPT-NAD-Sirtuin pathway in neuroblastoma chemoresistance, 2014. e-Pub 2014.
Cuglievan B, Galvez, J, Angulo D, G. Epstein Barr Infection obscuring Pediatric chronic eosinophilic leukemia associated t(1;5) with excellent response to targeted therapy, 2013. e-Pub 2013.
Morrison A, Cuglievan B, Khatib, Z. Intracranial calcifications in pediatric brain tumor patients after receiving proton beam therapy, 2013. e-Pub 2013.
Cuglievan B. MENIN INHIBITION IN PEDIATRIC KMT2AR LEUKEMIA: PHASE 1 AND EXPANDED ACCESS EXPERIENCE WITH REVUMENIB.
. Frontline Venetoclax Therapy for 18-Year-Old Male with Ataxia Telangiectasia and Early T-Cell Precursor Acute Lymphoblastic Leukemia. 65th Annual Meeting of the American-Society-of-Hematology (ASH).
Issa GC, Cuglievan B, DiPersio JF, Yu L, Jha S, Smith AR, Stein EM. Revumenib Activity in Patients With NUP98r Acute Myeloid Leukemia: Results From the AUGMENT-101 Phase 1 Study. 30th Annual Congress of the European Hematology Association.
Issa GC, Cuglievan B, DiPersio JF, Yu L, Jha S, Smith AR, Stein EM. Revumenib Activity in Patients With Acute Myeloid Leukemia With NUP98r: Results From the AUGMENT-101 Phase 1 Study. EHA 2025.
Issa GC, Cuglievan B, DiPersio JF, Yu L, Jha S, Smith AR, Stein EM. Revumenib Activity in Patients With Acute Myeloid Leukemia With NUP98r: Results From the AUGMENT-101 Phase 1 Study. SOHO 2025.
Aldoss I, Issa GC, Blachly JS, Thirman MJ, Mannis GN, Arellano ML, DiPersio JF, Traer E, Zwaan C, Shukla N, Cuglievan B, Grove CS, Greenwood M, McMahon CM, Perl AE, Stone RM, Papayannidis C, Dickens DS, Heiblig M, Žuèenka A, Montesinos P, Mantzaris I, Kovacsovics T, Shami PJ, Yu L, Bagley RG, Angela R Smith MD, Stein EM. Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenib in All Patients With Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia (AL). SOHO 2025.
Goulart H, Rausch C, Jabbour E, Maiti A, McCall D, Daver N, Short N, Pemmaraju N, Yilmaz M, Hammond D, Kornblau S, Issa G, Cuglievan B, Ravandi F, Kantarjian H. Multiarm Phase I study of the cyclin dependent kinase (CDK4/6) inhibitor palbociclib in combination for patients with relapsed and refractory acute leukemias. 67th Annual Meeting of the American-Society-of-Hematology (ASH).
Sheikh I, Raj R, Okeleji O, Catueno S, Fan A, McCall D, Gibson A, Garcia M, Connors J, Roth M, Nunez C, Petropoulos D, Cuglievan B, Tewari P. Positive outcomes associated with stem cell transplantation in pediatric/AYA patients who receive FLAG-IDA-venetoclax for high-risk AML. 67th Annual Meeting of the American-Society-of-Hematology (ASH).
Carter B, Mak PY, Mohanty V, Wu X, Nu Aye KT, Chen K, Cuglievan B, Andreeff M. Co-targeting menin and RAS in KMT2A-r/NPM1c AML with activated RTK//RAS/MAPK signaling. 67th Annual Meeting of the American-Society-of-Hematology (ASH).
Swaminathan M, Hill J, Sasaki K, Abbas H, Daver N, Kadia T, DiNardo C, Borthakur G, Jabbour E, Pemmaraju N, Valero YA, Ohanian M, Short N, Bose P, Takahashi K, Jen W, Pierce S, Cuglievan B, Ravandi F, Roth M. Overcoming barriers to clinical trial enrollment among adolescents and young adults with acute myeloid leukemia: Insights from a large academic cancer center. 67th Annual Meeting of the American-Society-of-Hematology (ASH).
McCall D, Hittle A, Cuglievan B, Jabbour E, Short N, Jain N, Catueno S, Garcia M, Nunez C, Roth M, Toepfer L, Torres R, Gibson A. Next-generation sequencing as a powerful tool for measurable residual disease assessment in pediatrics: Identifying time points of true remission. 67th Annual Meeting of the American-Society-of-Hematology (ASH).
Chohan K, Feng L, Cochran H, Rosenberg M, Isenalumhe L, Yilmaz E, Kim S, Tiger YK, Torka P, Flanagan H, Castellino S, Bender J, Kannaiyan R, Kahla J, DePriest B, Narvel H, Catueno S, Tobon K, Fadul J, Faulkenberry P, Ayers A, Nathan S, Mubeen S, Luttwak E, Flerlage J, Norris R, Kaur S, Tran O, Wannaphut C, Hawk A, Garcia M, Cuglievan B, Riedell P, Mahadeo K, Hamadani M, Diefenbach C, Bartlett N, Ahmed S. Real-world clinical outcomes with novel agent combination therapies for the frontline treatment of pediatric and adult advanced-stage Hodgkin lymphoma. 67th Annual Meeting of the American-Society-of-Hematology (ASH).
Cvrtak A, Nebral K, Boztug H, Abla O, Antoniou E, Buldini B, Czogala M, Haas VD, Gibson A, Gizhlaryan M, Goemans B, Haltrich I, Inaba H, Jacob N, Juul-Dam K, Kelaidi C, Klco J, Mühlegger N, Patel T, Pigazzi M, Scheidegger N, Zaliova M, Abrahamsson J, Cooper T, Cuglievan B, Moerloose BD, Gibson B, Hasle H, Kaspers G, Locatelli F, Petit A, Polychronopoulou S, Reinhardt D, Rubio P, Stary J, Tasian S, Tomizawa D, Dworzak M. Clinical, cytogenetic and molecular characteriszation of Mecom- rearranged pediatric de novo Acute Myeloid Leukemia (AML). 67th Annual Meeting of the American-Society-of-Hematology (ASH).
Catueno S, Qiu Y, Jenkins G, Camargo Magalhaes ED, Brown B, Garris R, Cuglievan B, Jabbour E, Short N, Horton T, Kornblau S. Protein expression signatures reveal age-specific risk patterns in B-ALL. 67th Annual Meeting of the American-Society-of-Hematology (ASH).
Garza M, Khazaei S, Munir F, Calkins P, Threat D, Mizuno H, Ostermann L, Cuglievan B, Garcia M, Ma L, Andreeff M, Nishida Y. Protein degradation of MYC/GSPT1 is a novel treatment modality for aggressive T-cell acute lymphoblastic leukemias. 67th Annual Meeting of the American-Society-of-Hematology (ASH).
Mill C, Fiskus W, Davis J, Birdwell C, Hou H, Wahlestedt C, Senapati J, Sasaki K, Loghavi S, Cuglievan B, Kadia T, Daver N, DiNardo C, Bhalla K. Identifying novel ‘druggable’ targets via Npm1A-turboid fusion and mass spectrometry to overcome genetic or adaptive resistance to menin inhibitors in mtNPM1 AML. 67th Annual Meeting of the American-Society-of-Hematology (ASH).
Aldoss I, Issa G, Blachly J, Thirman M, Mannis G, Arellano M, DiPersio J, Traer E, Zwaan C, Shukla N, Cuglievan B, Grove C, Greenwood M, McMahon C, Perl A, Stone R, Papayannidis C, Dickens D, Heiblig M, Zucenka A, Montesinos P, Mantzaris I, Kovacsovics T, Shami P, Yu L, Bagley R, Smith AR, Stein E. Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study. 67th Annual Meeting of the American-Society-of-Hematology (ASH).
Jen W, DiNardo C, Short N, Farhat A, Hajjar GE, Zhang B, Duose D, Daver N, Kadia T, Cuglievan B, Chien K, Jain N, Abbas H, Maiti A, Senapati J, Jabbour E, Montalban-Bravo G, Valero YA, Loghavi S, Ravandi F, Andreeff M, Garcia-Manero G, Kantarjian H, Issa G. Phase II Study of the all-oral combination of revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax (SAVE) in newly diagnosed AML. 67th Annual Meeting of the American-Society-of-Hematology (ASH).
Cuglievan B, Okeleji O, Catueno S, McCall D, Garcia M, Gibson A, Nunez C, Roth M, Farhat A, Hajjar GE, Garces S, Balch A, Stevens A, Yi J, Sasaki K, Sheikh I, Connors J, Petropoulos D, Tewari P, Issa G. Post-transplant maintenance with revumenib in children with HOX-driven AML. 67th Annual Meeting of the American-Society-of-Hematology (ASH).
Goulart H, Okeleji O, DiNardo CD, Daver N, Kadia TM, Bataller A, Kantarjian H, Abbas H, Jen WY, Nunez C, Connors JS, McCall D, Garcia-Manero G, Short NJ, Popat U, Petropoulos D, Tewari P, Al-Atrash G, Shpall E, Cuglievan B, Issa GC. Revumenib as Maintenance for AML Following Allogeneic Stem Cell Transplantation. American Society of Clinical Oncology.
. Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant. 65th Annual Meeting of the American-Society-of-Hematology (ASH).
. Targeted Protein Degradation for c-MYC Overcomes Therapy Resistance in T-Cell Acute Lymphoblastic Leukemias. 65th Annual Meeting of the American-Society-of-Hematology (ASH).
. Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemias: Efficacy and Safety Results from the Augment-101 Phase 1/2 Study. 65th Annual Meeting of the American-Society-of-Hematology (ASH).
. "Dose-Dense" Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves High Rates of Rapid MRD-Negativity in Patients with Philadelphia Chromosome-Negative B- Cell Acute Lymphoblastic Leukemia: A Retrospective Analysis.
. IFN. Signaling in Acute Myeloid Leukemia Mediates Immunomodulation and Reveals Therapeutic Strategies. 65th Annual Meeting of the American-Society-of-Hematology (ASH).
Aldoss I, Issa GC, Thirman M, DiPersio J, Arellano M, Blachly JS, Mannis GN, Perl A, Dickens DS, McMahon CM, Traer E, Zwaan C, Grove C, Stone R, Shami PJ, Mantzaris I, Greenwood M, Shukla N, Cuglievan B, Gu Y, Bagley RG, Madigan K, Sunkaraneni S, Nguyen HV, McNeer N, Stein EM. Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study. 65th Annual Meeting of the American Society of Hematology (ASH).
Cuglievan B, Nunez C, Ravandi F, McCall D, Gibson A, Garcia M, Roth M, Sheth R, Rabin K, Short N. Successful treatment with response-adjusted Venetoclax dosing in combination with Azacytidine and Gilteritinib in FLT3-ITD positive refractory AML. Abstracts from the 55th Congress of the International Society of Paediatric Oncology (SIOP) October 11–14, 2023.
Fiskus WC, Piel J, Hentemann M, Mill CP, Birdwell C, Das K, Davis J, Hou HX, Alhamadani N, Philip K, Matthews A, Kadia TM, Daver N, Loghavi S, Cuglievan B, DiNardo CD, Bhalla KN. Notable Efficacy of Co-Treatment with FHD-286, a Dual BRG1/BRM ATP-Ase Inhibitor, and Menin or BET Inhibitor, Decitabine or Venetoclax Against AML with MLL-r or Mutant NPM1. 65th Annual Meeting of the American-Society-of-Hematology (ASH).
Cuglievan B. Distinct Impact of Platinum Chemotherapies on the Fitness and Genome of Hematopoietic Stem Cells and the Risk of Therapy-Related Myeloid Neoplasms. 66th Annual Meeting of the American-Society-of-Hematology (ASH).
Cuglievan B. Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML. 66th Annual Meeting of the American-Society-of-Hematology (ASH).
Cuglievan B. Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia. 66th Annual Meeting of the American-Society-of-Hematology (ASH).
Cuglievan B. Identifying â€˜Druggableâ€™ Targets and Preclinically Overcoming Non-Genetic/Adaptive Resistance to Menin Inhibitors in AML with MLL1r or mtNPM1. 66th Annual Meeting of the American-Society-of-Hematology (ASH).
Cuglievan B. FLAG IDA Venetoclax in Newly Diagnosed Pediatric and AYA Patients with AML. 66th Annual Meeting of the American-Society-of-Hematology (ASH).
Cuglievan B. Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML. 66th Annual Meeting of the American-Society-of-Hematology (ASH).
Cuglievan B. Mortality after Diagnosis of Cardiovascular Disease in Survivors of Adolescent and Young Adult Lymphoma. 66th Annual Meeting of the American-Society-of-Hematology (ASH).
Cuglievan B. AUGMENT-101 Ph2 KMT2Ar. SFH 2025 Congress.
Aldoss I, Issa GC, Blachly JS, Thirman MJ, Mannis GN, Arellano ML, DiPersio JF, Traer E, Zwaan C, Shukla N, Cuglievan B, Grove CS, Greenwood M, McMahon CM, Perl AE, Stone RM, Papayannidis C, Dickens DS, Heiblig M, Žučenka A, Montesinos P, Mantzaris I, Kovacsovics T, Shami PJ, Yu L, Bagley RG, Smith AR, Stein EM. Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenib in All Patients With Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia (AL). EHA 2025 Congress.
Aldoss I, Issa GC, Blachly JS, Thirman MJ, Mannis GN, Arellano ML, DiPersio JF, Traer E, Zwaan C, Shukla N, Cuglievan B, Grove CS, Greenwood M, McMahon CM, Perl AE, Stone RM, Papayannidis C, Dickens DS, Heiblig M, Žuèenka A, Montesinos P, Mantzaris L, Kovacsovics T, Shami PJ, Yu L, Bagley RG, Smith AR, Stein EM. Updated Results and Longer Follow-Up From the AUGMENT-101 Phase 2 Study of Revumenibin Patients With Relapsed or Refractory (R/R) KMT2ArAcute Leukemia. 30th Annual Congress of the European Hematological Association.

Book Chapters

Cuglievan B, Osorio D, Brown B, Zaky W. Pediatric Cancers. In: Manual of Medical Oncology.

Books (edited and written)

Cuglievan, Zaky, Gorlick, Harrison. The fourth edition of The MD Anderson Manual of Medical Oncology, 2020.

Letters to the Editor

Frost M, Subbiah V, Cuglievan B, Garcia MB. Reconsidering Asparaginase in Leukemia Therapy. Acta Haematol: 1-5, 2026.
Cohen, E, Okeleji, O, McCall, DC, Garcia, MB, Nunez, CA, Cuglievan, B, Herzog, CE, Razvi, S, Tewari, P, Douglas, H, Gibson, A. Synchronous Mediastinal Germ Cell Tumor with Sarcomatous Transformation and Acute Myeloid Leukemia. Pediatric Blood and Cancer 72, 2025.
Nash A, Dinh CN, Kawedia J, McCall D, Weinman S, Garcia M, Roth M, Nunez C, Cuglievan B, Gibson A. Calasparagase Pegol Induced Hemolytic Anemia. Pediatr Blood Cancer 72: e31519, 2025.
Sheikh IN, Uwaezuoke D, Okeleji O, Quesada A, Herzog CE, Ragoonanan D, Tewari P, Petropoulos D, McCall D, Nunez C, Roth M, Cuglievan B, Khazal S. Treatment of a Pediatric Patient with Core Binding Factor Acute Myeloid Leukemia Post-Cytotoxic Therapy With Cytarabine, Daunorubicin, and Gemtuzumab Followed by Stem Cell Transplantation. Pediatr Blood Cancer 72: e31489, 2025.
Nasnas, PE, Ling, J, Gerstein, YS, Wang, S, Loghavi, S, Hammond, DE, Montalban Bravo, G, Senapati, J, Pemmaraju, N, Corredor, J, Pierce, S, Roth, M, Ravandi-Kashani, F, Cuglievan, B, Kadia, TM, DiNardo, C. Detection of PNH Clones can Aid in the Distinction of Aplastic Anemia vs Inherited BM Failure Syndromes. Clinical Lymphoma, Myeloma and Leukemia 24: 732-735, 2024.
Nash, A, Weirda, WG, Albritton, KH, Cuglievan, B, Garcia, MB, McCall, DC, Nunez, CA, Gibson, A. Rare case of chronic lymphocytic leukemia in an adolescent treated with targeted therapy. Pediatric Blood and Cancer 71, 2024.
Alqahtani, S, Ramakrishnan, R, Shuyu, E, Wang, S, Nunez, CA, McCall, DC, Garcia, MB, Roth, M, Cuglievan, B, Gibson, A. Venetoclax use in a patient with ataxia telangiectasia and early T-cell precursor acute lymphoblastic leukemia. Pediatric Blood and Cancer 71, 2024.
Okeleji O, Gibson A, Nunez C, Garcia MB, Roth M, Cuglievan B, McCall D. Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen. Pediatr Blood Cancer 71: e31091, 2024.
Alqahtani S, Ramakrishnan R, E S, Wang SA, Nunez C, McCall D, Garcia MB, Roth ME, Cuglievan B, Gibson A. Venetoclax use in a patient with ataxia telangiectasia and early T-cell precursor acute lymphoblastic leukemia. Pediatr Blood Cancer: e31123, 2024.
Ramakrishnan R, Munir F, Quesada AE, Hitzler J, Cuglievan B. Low-dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia. Pediatr Blood Cancer 71: e30974, 2024.
Sheikh, IN, Alqahtani, S, Yin, CC, McCall, DC, Cuglievan, B, Ragoonanan, D, Connors, JS, Gibson, A, Nunez, CA, Roth, M, Ohanian, M, Borthakur, G, Garcia, MB. KIT-mutated pediatric core-binding factor systemic mastocytosis-acute myeloid leukemia treated with avapritinib and decitabine. Pediatric Blood and Cancer 71, 2024.
Cuglievan B. Acute myeloid leukemia with inversion 16 and a novel PTPN11 mutation: A case report with literature review. International Journal of Laboratory Hematology 46: 195-198, 2023.
Cuglievan B, DePombo A, De Angulo G. Aplastic anemia: the correct nomenclature matters. Haematologica/haematol 101: e391, 2016.

Less

CV information above last modified March 31, 2026

Branko Cuglievan, MD

About Dr. Branko Cuglievan

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Review Articles

Other Articles

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Branko Cuglievan, MD

About Dr. Branko Cuglievan

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Review Articles

Other Articles

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson